Mustafa Al-Kawaaz1, Teresa Sanchez1,2, Michael J Kluk1. 1. Weill Cornell Medicine, Dept. of Pathology and Laboratory Medicine New York, NY, USA. 2. Weill Cornell Medicine, Dept. of Neuroscience, Brain and Mind Research Institute, New York, NY, USA.
Abstract
BACKGROUND: Aggressive, mature B-cell lymphomas include Burkitt Lymphoma (BL), High Grade B Cell Lymphomas (HGBL) (eg, Double-Hit B cell lymphomas (HGBL-DH: HGBL with MYC and BCL2 and/or BCL6 translocations)), HGBL, Not Otherwise Specified (HGBL, NOS) and Diffuse Large B Cell Lymphoma (DLBCL). Overlapping morphologic and immunohistochemical features of these lymphomas pose diagnostic challenges in some cases, and better understanding of potential diagnostic biomarkers and possible therapeutic targets is needed. Sphingosine 1 Phosphate Receptors (S1PR1-5) are G-protein coupled receptors that bind S1P and influence migration and survival in multiple cell types, including lymphocytes. S1PRs are emerging as biomarkers in B cell biology and interaction between S1PR pathways and STAT3 or FOXP1 has been reported in DLBCL. AIM AND METHODS: Our aim was to extend the understanding of S1PR1, STAT3 and S1PR2, FOXP1 expression beyond DLBCL, into additional aggressive, mature B cell lymphomas using immunohistochemical expression analysis of human tissue samples. RESULTS: S1PR1 and S1PR2 showed different expression patterns in mantle zones and follicle centers in reactive lymphoid tissue. BL showed a unique expression pattern compared to HGBL and DLBCL. Additionally, S1PR1 and S1PR2 expression were typically mutually exclusive and were expressed in a low proportion of cases (frequently HGBL involving extranodal sites). FOXP1 was expressed in a high proportion of various case types and pSTAT3 was detected in a significant proportion of HGBL and DLBCL. CONCLUSIONS: These findings provide further evidence that S1PR1, pSTAT3, S1PR2 and FOXP1 play a role in a subset of aggressive, mature B cell lymphomas.
BACKGROUND: Aggressive, mature B-cell lymphomas include Burkitt Lymphoma (BL), High Grade B Cell Lymphomas (HGBL) (eg, Double-Hit B cell lymphomas (HGBL-DH: HGBL with MYC and BCL2 and/or BCL6 translocations)), HGBL, Not Otherwise Specified (HGBL, NOS) and Diffuse Large B Cell Lymphoma (DLBCL). Overlapping morphologic and immunohistochemical features of these lymphomas pose diagnostic challenges in some cases, and better understanding of potential diagnostic biomarkers and possible therapeutic targets is needed. Sphingosine 1 Phosphate Receptors (S1PR1-5) are G-protein coupled receptors that bind S1P and influence migration and survival in multiple cell types, including lymphocytes. S1PRs are emerging as biomarkers in B cell biology and interaction between S1PR pathways and STAT3 or FOXP1 has been reported in DLBCL. AIM AND METHODS: Our aim was to extend the understanding of S1PR1, STAT3 and S1PR2, FOXP1 expression beyond DLBCL, into additional aggressive, mature B cell lymphomas using immunohistochemical expression analysis of human tissue samples. RESULTS: S1PR1 and S1PR2 showed different expression patterns in mantle zones and follicle centers in reactive lymphoid tissue. BL showed a unique expression pattern compared to HGBL and DLBCL. Additionally, S1PR1 and S1PR2 expression were typically mutually exclusive and were expressed in a low proportion of cases (frequently HGBL involving extranodal sites). FOXP1 was expressed in a high proportion of various case types and pSTAT3 was detected in a significant proportion of HGBL and DLBCL. CONCLUSIONS: These findings provide further evidence that S1PR1, pSTAT3, S1PR2 and FOXP1 play a role in a subset of aggressive, mature B cell lymphomas.
Authors: B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye Journal: Blood Date: 2007-10-19 Impact factor: 22.113
Authors: Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman Journal: Mod Pathol Date: 2011-05-06 Impact factor: 7.842
Authors: Giorgio Cattoretti; Jonathan Mandelbaum; Nancy Lee; Alicia H Chaves; Ashley M Mahler; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci; A John MacLennan Journal: Cancer Res Date: 2009-11-10 Impact factor: 12.701
Authors: Lloyd T Lam; George Wright; R Eric Davis; Georg Lenz; Pedro Farinha; Lenny Dang; John W Chan; Andreas Rosenwald; Randy D Gascoyne; Louis M Staudt Journal: Blood Date: 2007-12-26 Impact factor: 22.113
Authors: Yong Liu; Jiehui Deng; Lin Wang; Heehyoung Lee; Brian Armstrong; Anna Scuto; Claudia Kowolik; Lawrence M Weiss; Stephen Forman; Hua Yu Journal: Blood Date: 2012-06-28 Impact factor: 22.113
Authors: Heehyoung Lee; Jiehui Deng; Maciej Kujawski; Chunmei Yang; Yong Liu; Andreas Herrmann; Marcin Kortylewski; David Horne; George Somlo; Stephen Forman; Richard Jove; Hua Yu Journal: Nat Med Date: 2010-11-21 Impact factor: 53.440
Authors: Jesse A Green; Kazuhiro Suzuki; Bryan Cho; L David Willison; Daniel Palmer; Christopher D C Allen; Timothy H Schmidt; Ying Xu; Richard L Proia; Shaun R Coughlin; Jason G Cyster Journal: Nat Immunol Date: 2011-06-05 Impact factor: 25.606
Authors: Alfredo Pherez-Farah; Rosa Del Carmen López-Sánchez; Luis Mario Villela-Martínez; Rocío Ortiz-López; Brady E Beltrán; José Ascención Hernández-Hernández Journal: Cancers (Basel) Date: 2022-04-19 Impact factor: 6.575